Drug Profile
Research programme: human papillomavirus vaccine - Dynavax
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Dynavax Technologies
- Class Papillomavirus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Human papillomavirus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Human-papillomavirus-infections(Prevention) in USA
- 06 Jul 2010 Early research in Human papillomavirus infections in USA (unspecified route)